• Alda 1 and the Translational Logic of ALDH2

  2026-09-09

  Alda 1 illustrates how targeted ALDH2 activation can connect aldehyde detoxification with cardioprotection, cardiac regeneration research, and radiation-induced dermatitis mitigation. This thought-leadership perspective translates the emerging biology into practical study-design priorities while distinguishing preclinical promise from clinical readiness.

• ATP as a Metabolic Assay Variable

  2026-09-09

  Adenosine Triphosphate (ATP) is more than a cellular energy readout. This guide explains how to use ATP thoughtfully when studying TCAIM–OGDH regulation, mitochondrial proteostasis, and the distinction between altered energy state and altered enzyme abundance.

• Aprotinin for RBC Membrane Research

  2026-09-08

  Use Aprotinin to distinguish serine-protease effects from intrinsic red blood cell membrane mechanics, fibrinolysis, and inflammatory readouts. This practical workflow combines inhibitor titration, multiscale biophysics, and troubleshooting controls for more reproducible blood-cell research.

• Ac-YVAD-CMK Workflow for Caspase-1 Studies

  2026-09-07

  Ac-YVAD-CMK enables a practical way to separate caspase-1-driven cytokine maturation and pyroptosis from upstream plasma-membrane repair in Kupffer-cell infection models. This workflow combines inhibitor titration, membrane-integrity measurements, cytokine profiling, and genetic controls to clarify whether inflammatory injury is caspase-1 dependent.

• Cabazitaxel (XRP6258): Assay Workflow Guide

  2026-09-07

  Cabazitaxel (XRP6258, SKU B2157) provides a taxane-derived option for studying antiproliferative responses and microtubule dynamics disruption, including models with P-glycoprotein-associated taxane resistance. It is suited to controlled DMSO- or ethanol-based workflows, but not to water-only assays or long-term storage of prepared solutions.

• Cefazedone (Refosporen): From MIC to PK Insight

  2026-09-05

  Cefazedone (Refosporen) research is most informative when antibacterial testing is connected to pharmacokinetic exposure and assay quality. This article explains how to move from broth-dilution MIC data to defensible PK-PD interpretation using the cefazedone–etimicin LC-MS/MS study as a practical analytical framework.

• YAP–NF-κB–NLRP3 Control of UC Pyroptosis

  2026-09-04

  This study identifies a regulatory axis in which NF-κB p65 activates LATS1-dependent YAP phosphorylation, reducing YAP activity and its repression of NLRP3 in colonic epithelial cells. The findings connect Hippo-pathway signaling with GSDMD-mediated pyroptosis and suggest that epithelial YAP status is an important determinant of inflammatory injury in ulcerative colitis.

• Novel FLCN Mutations and mRNA Rescue in BHD

  2026-09-04

  A 2026 study identified a novel pathogenic FLCN nonsense variant and provided functional evidence that the previously uncertain p.W376R variant is pathogenic in two Chinese Birt-Hogg-Dubé families. In HEK293T cells, exogenous FLCN mRNA restored folliculin expression and corrected mTORC1 dysregulation, offering a preclinical rationale for mRNA-based protein replacement while leaving delivery and in vivo efficacy unresolved.

• Syringin Natural Product: RCC Assay Workflows

  2026-09-04

  Build reproducible renal cell carcinoma workflows around Syringin, from solvent handling and dose-response design to apoptosis and EGFR/PI3K/Akt pathway readouts. The approach distinguishes direct compound effects from sunitinib sensitization, making it useful for natural product research and bioactive compound screening.

• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-09-03

  Pladevall-Morera and colleagues identified a biomarker-linked vulnerability in high-grade glioma: cells lacking functional ATRX were more sensitive to several multi-targeted receptor tyrosine kinase and PDGFR inhibitors. The study also found enhanced toxicity when selected RTK inhibitors were combined with temozolomide, supporting ATRX status as a factor for interpreting targeted-therapy studies rather than as proof of clinical efficacy.

• Toremifene for Breast Cancer: 20 Years of Evidence

  2026-09-02

  The review by Vogel and colleagues synthesizes two decades of clinical experience with toremifene, emphasizing its role as a selective estrogen receptor modulator for postmenopausal patients with hormone-sensitive breast cancer. Its main contribution is a clinically focused comparison of efficacy, safety, pharmacokinetics, CYP2D6 metabolism, and tissue-selective effects, positioning toremifene as an alternative to tamoxifen and, in selected settings, aromatase inhibitors.

• Aspirin, Platelet TXA2, and T-Cell Control of Metastasis

  2026-09-02

  A 2025 Nature study identifies platelet-derived thromboxane A2 (TXA2) as an immunosuppressive signal that limits T-cell responses against early metastatic lesions through the guanine exchange factor ARHGEF1. Its genetic and pharmacological evidence explains how platelet COX-1 inhibition by aspirin can enhance anti-metastatic immunity, while also defining important boundaries for translation beyond the reported models.

• GDC-0941: A Mechanism-First Assay Strategy

  2026-09-01

  GDC-0941 is a selective PI3K inhibitor for dissecting PI3K/Akt signaling, pharmacodynamic response, and cancer cell proliferation inhibition. This guide adds a mechanism-first assay framework informed by recent pancreatic cancer research on pathway crosstalk, EMT, and combination effects.

• DRD4, Akt/β-Catenin, and Liver Cancer Resistance

  2026-09-01

  A 2024 study identifies DRD4 as a regulator of liver cancer stem cell-like traits, chemotherapy resistance, and tumorigenicity through the PI3K/Akt/GSK-3β/β-catenin axis. Its combined transcriptomic, clinical, pharmacological, genetic, and localization analyses support DRD4 pathway inhibition as a hypothesis for targeting resistant hepatocellular carcinoma populations.

• Alda 1: Reframing ALDH2 for Cardiac Repair

  2026-08-31

  Alda 1 offers translational researchers a mechanistically grounded way to interrogate ALDH2 in aldehyde detoxification, cardioprotection in ischemia, pressure-overload heart failure, and radiation-induced dermatitis mitigation. New evidence linking ALDH2 activation to cardiomyocyte proliferation expands the research agenda from acute protection toward cardiac repair.

8436 records 1/563 page Next 12345 下5页 Last page